Text Size

Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9

This study has been completed.
Sponsor:
Collaborator:
New York MDRU
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00015275
First received: April 18, 2001
Last updated: June 23, 2005
Last verified: December 2002
History of Changes
  Purpose

The purpose of this study is to define pathophysiological subtypes of abnormalities in subjects with cocaine dependence.


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
 Behavioral: Cocaine-Related Disorders
 Phase 4

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Pathophysiological Subtyping of Abnormalities in Cocaine Dependence

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Identification of homogenous subgroups within total population of cocaine dependent adults

Estimated Enrollment: 0
Detailed Description:

The objective of this study is to define subgroups of patients with differential treatment outcome on the basis of differential baseline electrophysiological clusters.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Cocaine dependence. Seeking residential treatment.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00015275

Locations
United States, New York
New York MDRU
New York, New York, United States, 10010
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
New York MDRU
Investigators
Principal Investigator: John Rotrosen, M.D. New York MDRU
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00015275     History of Changes
Other Study ID Numbers: NIDA-5-0013-9, Y01-5-0013-9
Study First Received: April 18, 2001
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Congenital Abnormalities
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Cocaine
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Dopamine Uptake Inhibitors
Dopamine Agents
 Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on June 18, 2013